5d 1m 3m 1y 5y 10y
There are no Transcripts on NWBO.
PR Newswire (Wed, 9:59AM)
PR Newswire (Feb 6, 2014)
NW Bio Enters Into Agreements For Large-Scale Expansion Of Product Manufacturing, Handling And DistributionPR Newswire (Jan 27, 2014)
PR Newswire (Jan 27, 2014)
PR Newswire (Jan 9, 2014)
PR Newswire (Dec 30, 2013)
PR Newswire (Dec 16, 2013)
NWBO vs. ETF Alternatives
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.
Wednesday, Mar 1212:47 PM
Wednesday, Mar 1211:15 AM
Wednesday, Mar 1210:34 AM|Wednesday, Mar 1210:34 AM| 22 Comments
Wednesday, Mar 129:13 AM|Wednesday, Mar 129:13 AM| 1 Comment
Tuesday, Mar 111:49 PM
Tuesday, Mar 1112:47 PM|Tuesday, Mar 1112:47 PM| Comment!
Tuesday, Mar 119:12 AM|Tuesday, Mar 119:12 AM| Comment!
Monday, Mar 1012:47 PM|Monday, Mar 1012:47 PM| 1 Comment
Monday, Mar 109:12 AM
Monday, Mar 108:25 AM
Monday, Mar 108:25 AM| 7 Comments
- Northwest Biotherapeutics (NWBO) gets a "Hospital Exemption" early access program for DCVax-L from German regulators. This means that the company may provide the product to patients for the treatment of Glioblastoma multforme and lower grades of gliomas outside of its clinical trial and charge full price.
- The approval term is five years.
- The German reimbursement authority approves DCVax-L eligibility for reimbursement from the Sickness Funds (health insurers). The specific level of payment will be negotiated by the company, hospitals and insurers.
Friday, Mar 79:12 AM
Friday, Mar 78:54 AM
Friday, Mar 78:54 AM| 2 Comments
- Shares of Northwest Biotherapeutics (NWBO) are poised for a strong up move at the open in response to its announcement that the Data Safety Monitoring Board recommends the continuation of its DCVax-L Phase 3 GBM trial.
- The unblinded review was conducted in response to shareholder inquiries.
- Prices have been on a roller coaster of late. In November, shares doubled, retraced, then shot up almost 150% to a February 27 peak of $7.92 before correcting. Shares closed yesterday at $5.96.
Monday, Jan 279:41 AM
Monday, Jan 279:41 AM| Comment!
- Northwest Biotherapeutics (NWBO) enters into agreements with long-time contract manufacturer Cognate Bioservices for the large-scale expansion of the manufacturing, storage, handling and distribution of Northwest's DCVax-L and DCVax-Direct products.
- The company believes that the agreements will give it a head start ahead of Phase III testing of its therapies. Cognate has a "12-year track record of regulatory and operational success with two dozen different cell product trials," Northwest says.
- The firm's DCVax products are personalized immune therapies for solid tumor cancers.
- Shares are +7.4%. (PR)
Monday, Jan 279:09 AM
Tuesday, Dec 172013, 9:11 AM
Tuesday, Dec 172013, 8:58 AM
Tuesday, Dec 172013, 8:58 AM| 6 Comments
- Shares of Northwest Biotherapeutics (NWBO) are suffering, off 7% in premarket action.
- Not helping the cause is TheStreet's Adam Feuerstein, who says DCVax "will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system."
- The thrust of the argument here is that positive data from early studies of the DCVax were misleading because the 20 brain cancer patients "were handpicked for treatment."
- Feuerstein says the same was true of a small Phase 1 study of ImmunoCellular's ICT-107, which ended up missing its primary OS endpoint in a larger study (triggering a spectacular sell-off last Wednesday).
- Feuerstein is responding to an article by SA contributor Josh Ginsburg who, on Monday, explained why he thinks NWBO "is different."